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Background: The aim of this study was to evaluate the efficacy and tolerability of fulvestrant, an estrogen receptor
antagonist, in postmenopausal women with hormone-responsive tumors progressing after aromatase inhibitor (AI)
treatment.
Patients and methods: This is a phase II, open, multicenter, noncomparative study. Two patient groups were
prospectively considered: group A (n = 70) with AI-responsive disease and group B (n = 20) with AI-resistant disease.
Fulvestrant 250 mg was administered as intramuscular injection every 28 (±3) days.
Results: All patients were pretreated with AI and 84% also with tamoxifen or toremifene; 67% had bone metastases
and 45% liver metastases. Fulvestrant administration was well tolerated and yielded a clinical benefit (CB; defined
as objective response or stable disease [SD] for ‡24 weeks) in 28% (90% confidence interval [CI] 19% to 39%) of
patients in group A and 37% (90% CI 19% to 58%) of patients in group B. Median time to progression (TTP) was
3.6 (95% CI 3.0 to 4.8) months in group A and 3.4 (95% CI 2.5 to 6.7) months in group B.
Conclusions: Overall, 30% of patients who had progressed following prior AI treatment gained CB with fulvestrant,
thereby delaying indication to start chemotherapy. Prior response to an AI did not appear to be predictive for benefit
with fulvestrant.
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introduction
Most patients with breast cancer have tumors that express
estrogen receptors (ERs) and/or progesterone receptors (PgRs)
and therefore can potentially benefit from hormonal therapy.
Sequential hormonal treatment represents an established
approach for hormone-responsive advanced breast cancer
(ABC). In postmenopausal patients, tamoxifen, nonsteroidal
(anastrozole or letrozole) and steroidal (exemestane) aromatase
inhibitors (AIs), are effective [1]. As it is well tolerated,
endocrine therapy is the treatment of choice for patients
without extensive visceral metastasis and those who cannot
endure chemotherapy. A major concern with endocrine
treatments is that some tumors are de novo hormone resistant
and most acquire resistance eventually [2, 3]. The development
of new non-cross-resistant endocrine agents is thus urgently
required, especially as tamoxifen, AIs or both are now
increasingly used in the adjuvant setting [4, 5].
Fulvestrant (Faslodex; AstraZeneca Pharmaceuticals,
Macclesfield, UK) is a steroidal analogue of 17-beta-estradiol.
When fulvestrant binds to the ER, it induces a conformational
change preventing receptor dimerization. The receptor is
rapidly degraded, resulting in a decrease of cellular ER levels.
Fulvestrant disables the function of both transcriptional
activating factors, AF1 and AF2, and has no estrogen agonist
activity contrary to selective estrogen receptor modulators
[6, 7]. A major mechanism of resistance to tamoxifen consists
of mitogen-activated protein kinase and PI3K/AKT pathways
activation by epidermal growth factor receptor (EGFR) and
human EGFR-2 (HER2). In vitro models have indicated that
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studies, the efficacy of fulvestrant in patients with ER-positive
ABC has been shown at first-line [9] and second-line [10–12]
therapy with similar efficacy to tamoxifen and AI, respectively.
The present study aimed at assessing the efficacy of fulvestrant
in postmenopausal patients with ABC progressing after
treatment with a steroidal or nonsteroidal AI.
patients and methods
study design
This was a phase II open, multicenter, noncomparative study, conducted at
eight centers in three countries. Patients were recruited from March 2000 to
June 2004, and data cut-off was June 2005. The trial was designed and
monitored in accordance with good clinical practice and the Declaration
of Helsinki. It was approved by an Independent Ethics Committee at
each center, and written informed consent was obtained from all
participants.
patients
The study population included postmenopausal women with metastatic
disease who had histological or cytological confirmation of breast cancer.
Postmenopause was defined as women older than 55 years or older than
45 years and amenorrhea >12 months or with biochemical evidence of
postmenopausal hormonal status or having undergone bilateral
oophorectomy. All patients had objective evidence of disease progression
after ‡12 weeks of treatment with a steroidal or nonsteroidal AI. Further
eligibility criteria included evidence of hormone sensitivity with tumor
expression of ER and/or PgR, previous ‡12-months adjuvant hormonal
treatment before relapse and tumor regression or stabilization for ‡3 months
during endocrine therapy. Adequate liver, renal and bone marrow function
were also mandatory for inclusion.
Patients with life-threatening visceral metastases (e.g. extensive hepatic or
pulmonary involvement or symptomatic pulmonary lymphangitic spread)
or a history of brain or leptomeningeal involvement were not eligible.
Previous treatment with fulvestrant, previous endocrine therapy with
progestin, estrogens, androgens or treatment of breast cancer with more
than two different hormonal agents was not accepted. Patients who had
received more than one line of chemotherapy for ABC before AI treatment
were excluded. Bone-only disease was accepted in the absence of
bisphosphonates.
treatment schedule
Patients received fulvestrant 250 mg as a single 5-ml intramuscular injection
every 28 (±3) days until objective evidence of disease progression,
withdrawal from the trial due to an unacceptable adverse event (AE) or
withdrawal of patient consent.
efficacy and safety evaluations
Patients were evaluated prospectively in two different groups for which the
expected response rate was different:
• Group A: AI-responsive patients, defined as patients who had
progressed while on an AI (anastrozole, letrozole, exemestane or
formestane) treatment of ABC after initially experiencing an
objective response (OR) or stable disease (SD) for
‡24 weeks.
• Group B: AI-resistant patients, defined as patients who did not respond to
AI treatment of ABC or those who had SD for <24 weeks.
World Health Organisation (WHO) criteria were used for tumor
assessment. Initially, the primary end point of the trial was evaluation of
the efficacy of fulvestrant in terms of OR rate, duration of response, time
to progression (TTP) and time to treatment failure (TTF). After an
interim analysis in March 2002, a relatively frequent sustained clinical
benefit (CB) was observed despite a low OR rate. The study committee
thus judged that CB, defined as OR (complete or partial response [CR or
PR]) or SD for ‡24 weeks, was a clinically relevant end point by
potentially postponing for >6 months the need for chemotherapy in this
patients group, who had already received two lines of hormonotherapy
for most of them. Therefore, the primary end point was changed to CB
rate. The sample sizes for groups A and B were then recalculated. This
amendment was submitted to and approved by the Independent Ethics
Committees.
Tolerability (local and systemic) and safety of fulvestrant were also
assessed.
Clinic visits took place at screening, on day 1 and then every 28 ± 3 days.
Screening assessment included medical history, chest X-ray or thoracic
computed tomography (CT) scan, isotopic bone scan or skeletal survey,
hematology and biochemistry assessments, tumor assessment and WHO
performance status (PS). Patients with elevated liver enzymes at screening
were further evaluated with a liver ultrasound or abdominal CT scan.
Objective tumor assessments were made at each visit for the first 3 months of
treatment in those patients with disease that could be assessed by physical
examination. Radiological assessments of the tumor were carried out every
third month until disease progression.
Duration of CB was calculated from the date of registration to the date of
objective progression or death before objective progression. TTF was
measured from registration to treatment withdrawal from any cause. TTP
was calculated from registration to progression. Patients were monitored for
clinical and laboratory toxic effects at each visit and also for 8 weeks
following their final injection of fulvestrant. Drug-related AEs were
considered to be any documented change in a patient’s condition during the
study period that had a reasonable possibility of being caused by the trial
treatment. All AEs were graded according to their intensity on the basis
of the CTC AE version 2.0 grading and were monitored until the end of
the follow-up period.
specific assessments
Tumor samples were analyzed centrally (Institut de Pathologie, Centre
Hospitalier Universitaire Vaudois, Lausanne, Switzerland, with Maryse
Fiche, MD, as the responsible pathologist) for HER2 protein status using
immunohistochemistry (HercepTest; Dako, Glostrup, Denmark). Tumors
with a 2+ score were also analyzed using FISH to confirm HER2 status
(PathVysion; Abbott AG, Baar, Switzerland).
statistical plan
The size of the trial population was based on the primary end point (CB
rate), and calculated separately for each group. In group A, we expected a CB
rate of 35%–45%. For a 90% confidence interval (CI) of ±10%, a sample size
of 68 patients was required. Group A was closed on 8 January 2004 due to
completed accrual. In group B, we expected a CB rate of 25%–30%.
According to an optimal two-stage MinMax design [13], a total of 25
patients were required (amendment 3 of April 2002). Accrual in group B,
however, was slower than expected due to the nature of the disease
observed in patients not responding to AIs, often requiring chemotherapy
rather than third-line hormonal treatment. In light of this difficulty,
group B was closed early on 23 June 2005, after the inclusion of 20 patients.
CIs for CB rates were calculated using the Clopper–Pearson method [14].
Duration of treatment, CB, TTF and TTP were analyzed using the
Kaplan–Meier method. As an exploratory analysis, Fisher’s exact test was
carried out to investigate the association between CB and selected baseline
characteristics (e.g. age, sites of metastases, HER2 status) in group A.
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results
patients
A total of 90 patients were included in the study, 70 in group A
and 20 in group B. Three patients from group A and one patient
from group B did not meet the inclusion criteria; therefore,
there were in total 86 eligible patients. Sixty-two patients (72%)
had a WHO PS of 0 and 22 patients (26%) a PS of 1. Other
patient characteristics are summarized in Table 1.
Fifty-six (84%) patients in group A received tamoxifen
(n = 54), toremifene (n = 1) or goserelin (n = 1) as treatments
in the adjuvant and/or first-line metastatic settings. In that
group, all but one patient received an AI in the metastatic
setting before inclusion in the trial. The remaining patient
received tamoxifen and letrozole in the adjuvant setting and
then relapsed under therapy. The vast majority of patients
(82%) received a nonsteroidal AI (anastrozole or letrozole);
only 12 patients (18%) received a steroidal AI (exemestane).
In group B, 17 patients (89%) received tamoxifen either in
the adjuvant setting or as first-line hormonal treatment of
metastatic disease. All patients except one received an AI in the
metastatic setting. The remaining patient received letrozole for
13 months as adjuvant therapy before relapse.
Most patients in both groups had bone metastases (70% in
group A and 58% in group B). A significant number of
patients had visceral disease, with 46% of patients in group A
and 42% of patients in group B having liver metastases. Two
patients were included in spite of an ER- and PgR-negative
tumor because their long clinical history indicated hormonal
sensitivity, but no CB was observed. They have been
incorporated for results analysis.
efficacy
Sixty-three of the 67 patients in group A and all of the patients in
group B were evaluable for the assessment of response (Table 2).
In group A, one patient experienced a PR and 18 had SD ‡24
weeks, resulting in a CB rate of 28% (90% CI 19% to 39%).
Of note, 11 patients (16%) had a SD for >36 weeks and six
patients (9%) for >1 year. In group B, to conclude that the
treatment was promising, we needed at least six responders
out of 25 patients and this number is reached already in the
sample of 19 patients. One patient with bilateral lung metastasis
experienced a CR and was still receiving treatment >52 weeks
after registration; six other patients had SD ‡24 weeks, resulting
in a CB rate of 37% (90% CI 19% to 58%). Interestingly, three
patients (16%) had SD for >36 weeks in this group.
The median number of fulvestrant injections per patient was
four (range: 1–53 in group A; 2–18 in group B), with 456
injections in total in group A and 118 in group B. Overall, the
median duration of treatment was 3.8 (range: 0.9–52) months in
group A and also 3.8 months in group B (range: 1.8–17.9+
Table 1. Patient and disease characteristics at baseline
Group A, n (%) Group B, n (%)
Eligible patients 67 19
Median age, years (range) 65 (44–84) 70 (39–86)
Tumor localizationa
Breast 14 (21) 8 (42)
Skin 13 (19) 5 (26)
Bone 47 (70) 11 (58)
Liver 31 (46) 8 (42)
Lung 17 (25) 5 (26)
Lymph nodes 31 (46) 8 (42)
Others 18 (37) 5 (26)
Metastatic sites: 1 versus 2–3 versus >3 14 (21) versus 39 (58) versus 14 (21) 4 (21) versus 8 (42) versus 7 (37)
Tumor hormone receptor status
ER+ and PgR+ 45 (67) 14 (74)
ER+ and PgR 12 (18) 2 (11)
ER and PgR+ 0 (0) 0 (0)
ER and PgRb 1 (1) 1 (5)
HER2/neu positive 4 (6) 2 (11)
Prior radiotherapy 27 (40) 7 (37)
Prior hormonal therapy
Adjuvant Ta, To or G 26 (39) 6 (32)
Adjuvant and/or metastatic Ta, To or G 56 (84) 17 (89)
Adjuvant AI 1 (1) 1 (5)
AI for metastatic disease 66 (99) 18 (95)
Nonsteroidal AI (anastrozole or letrozole) 54 (81) 12 (63)
Steroidal AI (exemestane) 12 (18) 6 (32)
Prior chemotherapy for metastatic disease 24 (36) 6 (32)
aMultiple sites possible.
bPatient’s medical history indicated the presence of a potentially hormone-responsive tumor.
ER, estrogen receptor; , negative; +, positive; PgR, progesterone receptor; Ta, tamoxifen; To, toremifene; G, goserelin; AI, aromatase inhibitor.
original article Annals of Oncology
66 | Perey et al. Volume 18 | No. 1 | January 2007
months). The median TTP was similar in both groups: 3.6
months (95% CI 3.0–4.8 months) for patients in group A and
3.4 months (95% CI 2.5–6.7 months) for those in group B.
The median TTF was 3.6 (95% CI 3.0–4.6) and 3.4 (95% CI
2.5–6.7) months in groups A and B, respectively. Reasons for
discontinuing fulvestrant treatment are presented in Table 3.
Altogether, for >90% of patients, the reason for discontinuing
fulvestrant was disease progression.
When looking retrospectively for factors potentially
predictive of CB to fulvestrant, we found that only 11 of the
53 patients (21%) in group A with multiple sites of metastases
experienced a CB versus eight of the 14 patients (57%) with one
site of involvement (P = 0.02; Fisher’s exact test). The presence
of liver or lung metastases and type of AI treatment received
(steroidal versus nonsteroidal) did not seem to influence
treatment efficacy, but age appeared to be a predictive factor for
CB. Two of the 23 patients <60 years of age (9%) had CB with
fulvestrant versus 17 of the 44 patients ‡60 years of age (39%).
This consists of a univariate analysis.
HER2 status
HER2 status was determined in 54 patients in group A and 17
patients in group B. The vast majority of patients (93%) had
HER2-negative tumors. None of the six patients with HER2-
positive disease (HercepTest 3+) reached CB with fulvestrant.
Four cases with a 2+ score did not show amplification by FISH
and were considered negative. Among patients with HER2-
negative status, 16 of 50 (32%) in group A and six of 15 patients
(40%) in group B had CB.
tolerability and safety
All eligible patients who received at least one injection of
fulvestrant were included in the safety analysis. Fulvestrant
treatment was well tolerated and only two patients
discontinued treatment due to AE. Drug-related AEs occurring
in patients in both groups are shown in Table 4. All patients
experienced grade 1–2 side effects but only three patients (3%)
had grade 3 events: injection-site reaction (n = 1), hot flashes
(n = 1) and transient ischemic attack (n = 1). The transient
ischemic attack was possibly related to fulvestrant, which was
then discontinued.
discussion
Three major findings have emerged from this multicenter, phase
II study. First, fulvestrant at the registered dose of 250 mg
repeated every 28 days is effective in this group of hormonally
pretreated patients with 30% of them experiencing CB. Second,
previous response to an AI does not appear to be predictive for
fulvestrant efficacy since CB rates were similar for patients in
group A (those who had previous benefit with an AI) and group
B (those who had primary resistance to AIs): 28% (90% CI 19%
to 39%) versus 37% (90% CI 19% to 58%), respectively. Third,
fulvestrant is well tolerated with only three patients (3%)
developing grade 3 toxicity, two of which required therapy to be
discontinued. The most frequent side effects with fulvestrant
were hot flashes, fatigue, appetite loss and transient discomfort
at the injection site, which were mild or moderate in intensity.
The most frequent reason for discontinuing treatment was
disease progression (92%). This tolerability profile is similar
with that previously reported in other trials of fulvestrant [15].
The results of this final analysis are consistent with our
preliminary results [16] and those of the North Central Cancer
Treatment Group (NCCTG) N0032 study in patients receiving
fulvestrant after progression on an AI ± tamoxifen [17]. In that
study, 35% of patients receiving fulvestrant experienced CB,
Table 2. Efficacy of fulvestrant
Group A Group B
SD ‡24 weeks, n (%) 18 (27) 6 (32)
PR, n (%) 1 (1) 0 (0)
CR, n (%) 0 (0) 1 (5)
Disease progressiona, n (%) 44 (66) 12 (63)
Not assessable, n (%) 4b (6) 0 (0)
CB, n [% (90% CI)] 19 [28 (19–39)] 7 [37 (19–58)]
Median duration of CB, months
(range)c
10.8 (5.6–50.1) 9.0 (5.5–17.0)
Median TTP, months (95% CI) 3.6 (3.0–4.8) 3.4 (2.5–6.7)
Median TTF, months (95% CI) 3.6 (3.0–4.6) 3.4 (2.5–6.7)
Median duration of treatment,
months (range)
3.8 (0.9–52) 3.8 (1.8–17.9+)
aDisease progression also includes patients with SD for <24 weeks.
bOne patient withdrew consent and decided to participate in another
protocol, two patients were lost to follow-up, one patient discontinued
treatment following an adverse event.
cMeasured from registration to disease progression.
CB, clinical benefit; CI, confidence interval; CR, complete response;
PR, partial response; SD, stable disease; TTP, time to progression;
TTF, time to treatment failure.





Disease progression 61 (91) 18 (95)
Adverse events 2 (3) 0 (0)
Patient refusal 2 (3) 0 (0)
Lost to follow-up 2 (3) 0 (0)
aOne patient (5%) is still receiving treatment.
Table 4. Incidence of drug-related adverse events
All grades, n (%) Grade 3a, n (%)
Hot flashes 14 (16.3) 1 (1.2)
Fatigue 8 (9.3) –
Injection-site pain 6 (7.0) –
Loss of appetite 4 (4.7) –
Nausea 1 (1.2) –
Injection-site inflammation 1 (1.2) 1 (1.2)
Transient ischemic attack 1 (1.2) 1 (1.2)
Vaginal dryness 1 (1.2) –
aAll grade 3 adverse events occurred in group A.
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including 14% with an OR. The CB rates in the SAKK and the
NCCTG trials fit well, confirming the reproducibility of the
results; however, the OR rates were distinct. The difference in
terms of OR rate between the two studies is not totally clear but
may be related to differences in patient characteristics, e.g.
proportion of patients with bone metastases, number and
localization of metastases, incidence of HER2-positive disease
and previous tamoxifen treatment. The two studies used
different criteria for tumor assessment (WHO versus RECIST,
respectively). This, however, should not significantly modify
the OR rate [18]. Another possible factor of the lower OR rate
observed in our study compared with others might be that 58
patients (67%) had bone metastases as part of systemic
dissemination of their disease, including eight patients as unique
metastatic site. Because of a restriction of technical resources in
this multicenter study, we did not use changes in bone
scintigraphy or magnetic resonance imaging to precisely assess
bone response as reported by others [19]. This may have
resulted in a relative underreporting of responses in bone.
Franco et al. [20] described their single-center experience of
using fulvestrant in heavily pretreated postmenopausal patients,
as part of a compassionate-use program. In line with the
hypothesis that the level of pretreatment may affect OR rate, no
ORs were reported in this study, although 19% of patients had
SD ‡ 24 weeks. A report from a single Austrian center [19],
involved in the fulvestrant compassionate-use program,
described a CB rate of 43.5% in patients receiving fulvestrant as
second-, third- or fourth-line endocrine therapy after prior
endocrine therapy, usually including a nonsteroidal AI. The
Austrian study also indicated that the CB rate was independent
of the number of prior lines of endocrine treatment, but that the
OR rate was lower when fulvestrant was given later in the
sequence. In our study, previous response to an AI did not
appear to be predictive of the effectiveness of fulvestrant.
Indeed, with seven patients among 20 presenting a response or a
SD of ‡6 months, fulvestrant shows clearly to have an activity
against tumors with primary resistance to AIs. The percentage
of CB, however, has yet to be interpreted with caution because
of the low number of patients in this group and the potential
risk of selection bias. One-third of the patients had SD ‡24
weeks and almost 10% of those in group A had CB for >1 year.
One responding patient in group B has been receiving treatment
for 18 months at the time of data cut-off. This indicates that
fulvestrant can overcome initial and acquired resistance to AIs
and that both groups of patients may benefit from treatment.
Our results are therefore particularly relevant to clinical practice
since the third-generation AIs, anastrozole, letrozole and
exemestane, are increasingly being used as adjuvant therapy for
breast cancer on the basis of recently published randomized trial
data [21–26]. Because of this change in clinical practice, new
endocrine strategies for relapsing patients with ER-positive
tumors are urgently needed.
In our study, as in the NCCTG study, only a small proportion
of patients, six out of 71 patients, had HER2-positive tumors.
This is expected in a patient population selected according to
endocrine responsiveness of the disease. None of them had CB
with fulvestrant; however, firm conclusions on the activity of
fulvestrant in this setting cannot be drawn based on such small
numbers. Indeed other preliminary data have shown that HER2
positivity did not preclude response to fulvestrant [19]. The
efficacy of fulvestrant has also been demonstrated in other
clinical situations. In the first-line setting, fulvestrant had
similar efficacy to tamoxifen in patients with ER-positive
ABC [9]. In second line, fulvestrant is the only ER antagonist
that has demonstrated efficacy after tamoxifen failure [27].
Furthermore, fulvestrant was as effective and well tolerated as
anastrozole after a first-line hormonal therapy (mainly with
tamoxifen) [10–12]. As third-line endocrine treatment, in
patients progressing after aminoglutetimide [28] or after
nonsteroidal AI treatment [29, 30], exemestane has also
shown valuable benefit. The ongoing Evaluation of Faslodex
and Exemestane Clinical Trial (EFECT) compares fulvestrant
and exemestane in patients progressing after nonsteroidal AI
treatment.
In conclusion, by inducing a CB in 30% of patients with
hormone receptor-positive tumors having received prior
steroidal and nonsteroidal AI and most of them having also been
exposed to tamoxifen, fulvestrant emerges as an interesting and
potentially important player in the sequential endocrine
treatment of ABC. In this population of women with lower
tumor burden, which does not require immediate use of
chemotherapy, delaying >6 months the use of chemotherapy
by using monthly injections of fulvestrant is a valuable
approach to keep an optimal quality of life.
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